| 11-14-2006 04:12 PM CET - Health & Medicine |
|
Generic Brand Acetaminophen Recall
Press release from: The Rasansky Law Firm
PR Agency: Page One
(openPR) - The U.S. Food and Drug Administration (FDA) is informing the public to a recall by Perrigo Company (Perrigo) of Allegan, Michigan for 383 lots of acetaminophen 500mg caplets manufactured and distributed under various generic or store brands due to small metal fragments found in the acetaminophen. An estimated 11 million bottles are affected by this recall. For a list of acetaminophen recall, see www.fda.gov/oc/po/firmrecalls/perrigo/perrigobatchlist.html. Consumers can determine if they are in possession of a recalled acetaminophen by locating the batch number printed on the container label. A list of stores that carry generic or store brands affected by this acetaminophen recall is located on FDA's website at www.fda.gov/oc/po/firmrecalls/perrigo/perrigocustlist.html.
As of November 9, 2006, there have been no illness or injuries reports due to the acetaminophen recall. The FDA believes the probability of serious adverse health consequences casued by the acetaminophen is remote. If swallowed, an affected acetaminophen caplet could cause in stomach discomfort and/or cuts to the mouth or throat. Consumers should consult their physician if they suspect they've been harmed by use of this product.
Consumers in possession of the affected products should stop use immediately and contact Perrigo at 877-546-0454. Adverse reactions experienced with the use of the acetaminophen caplets should be reported to Perrigo and the FDA's MedWatch Program by phone at 800-FDA-1088, by fax at 800-FDA-0178 or on the MedWatch website at www.fda.gov/medwatch.
The FDA is investigating the cause of the metal fragments found in the acetaminophen caplets. Perrigo informed FDA of metal contamination of the acetaminophen caplets. The cause is suspected to be premature wear of manufacturing equipment. Perrigo has discovered approximately 200 caplets containing metal fragments ranging in size from "microdots" to portions of wire 8 mm in length.
The FDA does not anticipate that the acetaminophen recall will cause a shortage of acetaminophen.
The Rasansky Law Firm
2525 McKinnon Suite 625
Dallas, TX 75201
www.texasinjuryattorney.com
Contact: Alyssa Journey / 1-800-704-3578
The Rasansky Law Firm, located in Dallas, represents personal injury victims who have been devastated by the misconduct of others.
As of November 9, 2006, there have been no illness or injuries reports due to the acetaminophen recall. The FDA believes the probability of serious adverse health consequences casued by the acetaminophen is remote. If swallowed, an affected acetaminophen caplet could cause in stomach discomfort and/or cuts to the mouth or throat. Consumers should consult their physician if they suspect they've been harmed by use of this product.
Consumers in possession of the affected products should stop use immediately and contact Perrigo at 877-546-0454. Adverse reactions experienced with the use of the acetaminophen caplets should be reported to Perrigo and the FDA's MedWatch Program by phone at 800-FDA-1088, by fax at 800-FDA-0178 or on the MedWatch website at www.fda.gov/medwatch.
The FDA is investigating the cause of the metal fragments found in the acetaminophen caplets. Perrigo informed FDA of metal contamination of the acetaminophen caplets. The cause is suspected to be premature wear of manufacturing equipment. Perrigo has discovered approximately 200 caplets containing metal fragments ranging in size from "microdots" to portions of wire 8 mm in length.
The FDA does not anticipate that the acetaminophen recall will cause a shortage of acetaminophen.
The Rasansky Law Firm
2525 McKinnon Suite 625
Dallas, TX 75201
www.texasinjuryattorney.com
Contact: Alyssa Journey / 1-800-704-3578
The Rasansky Law Firm, located in Dallas, represents personal injury victims who have been devastated by the misconduct of others.
News-ID: 12805
More releases
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
The Rasansky Law Firm
Comments about openPR
We publish our press releases on openPR.de because we like people who are "open" - just like us.
Frank Obels, CEO, INCONET - Informationssysteme, Communication und Netzwerkberatung GmbH
Frank Obels, CEO, INCONET - Informationssysteme, Communication und Netzwerkberatung GmbH

